Literature DB >> 11906190

Expression profile analysis of colon cancer cells in response to sulindac or aspirin.

Masayoshi Iizaka1, Yoichi Furukawa, Tatsuhiko Tsunoda, Hirofumi Akashi, Michio Ogawa, Yusuke Nakamura.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) have a preventive effect against colorectal cancer. Although inhibition of cyclooxygenase-2 plays a crucial role in the suppression of tumors, precise mechanisms of their action remain to be disclosed. To identify genes involved in the growth-suppressive effect of NSAIDs, we utilized cDNA microarray containing 23,040 genes and analyzed time-dependent alteration of gene expression in response to sulindac or aspirin in NSAIDs-sensitive SW480 and SW948 colon-cancer cells as well as in relatively resistant SNU-C4 cells. Consequently we identified 112 genes with commonly altered expression by sulindac and 176 with commonly altered expression by aspirin in the three lines. Addition of sulindac and that of aspirin altered expression levels of 130 and 140 genes, respectively, in SW480 and SW948 cells but not in SNU-C4 cells. These data may lead to a better understanding of growth-suppressive effects on colonic epithelium, and may provide clues for identifying novel therapeutic and/or preventive molecular targets of colon cancer. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906190     DOI: 10.1006/bbrc.2002.6648

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Difference of gene expression profiles between esophageal carcinoma and its pericancerous epithelium by gene chip.

Authors:  Shen-Hua Xu; Li-Juan Qian; Han-Zhou Mou; Chi-Hong Zhu; Xing-Ming Zhou; Xiang-Lin Liu; Yong Chen; Wen-Yu Bao
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells.

Authors:  Alun Hughes; Nicholas I Smith; Heather M Wallace
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

3.  Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice.

Authors:  Hector Guillen-Ahlers; Steven A Buechler; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  Carcinogenesis       Date:  2008-05-21       Impact factor: 4.944

4.  Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.

Authors:  James Todd Auman; Robert Church; Soo-Youn Lee; Mark A Watson; James W Fleshman; Howard L Mcleod
Journal:  Eur J Cancer       Date:  2008-07-22       Impact factor: 9.162

5.  Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer.

Authors:  G A Doherty; S M Byrne; S C Austin; G M Scully; D M Sadlier; T G Neilan; E W Kay; F E Murray; D J Fitzgerald
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

6.  Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells.

Authors:  Marjan J Van Erk; Eva Teuling; Yvonne CM Staal; Sylvie Huybers; Peter J Van Bladeren; Jac MMJG Aarts; Ben Van Ommen
Journal:  J Carcinog       Date:  2004-05-12

7.  Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors.

Authors:  Xi Li; Satya S Pathi; Stephen Safe
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

8.  Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells.

Authors:  Charles S Fuchs; Zhi Rong Qian; Shuji Ogino; Mancang Gu; Reiko Nishihara; Yang Chen; Wanwan Li; Yan Shi; Yohei Masugi; Tsuyoshi Hamada; Keisuke Kosumi; Li Liu; Annacarolina da Silva; Jonathan A Nowak; Tyler Twombly; Chunxia Du; Hideo Koh; Wenbin Li; Jeffrey A Meyerhardt; Brian M Wolpin; Marios Giannakis; Andrew J Aguirre; Adam J Bass; David A Drew; Andrew T Chan
Journal:  Oncotarget       Date:  2017-09-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.